Vertex Pharmaceuticals, Inc. (VRTX) Misses Q1 EPS by 11c

Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q1 EPS of $0.55, $0.11 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $438.7 million versus the consensus estimate of $473.37 million.

Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• Capitol Federal Financial names William Skrobacz Jr. as president
• Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)